Company profile for GBS

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes.GBS Inc. is a member of The iQ Group Global, an award-winning consort...
GBS Inc. is on a mission to put the power of non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at point of care. With the world-first Biosensor Platform, GBS Inc. is developing and launching diagnostic tests urgently needed to help eradicate COVID-19 and change the lives of people living with diabetes.GBS Inc. is a member of The iQ Group Global, an award-winning consortium of companies that finds, funds and develops innovative bioscience intellectual property from world-class academic institutions to create life-changing medical innovations.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
420 Lexington Ave, Suite 300, New York, NY 10170
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

BPI Europe

BPI Europe

Not Confirmed

envelop Contact Supplier

BPI Europe

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2022/10/04/2527914/0/en/GBS-Inc-Acquires-Intelligent-Fingerprinting-Limited-and-its-Proprietary-Drugs-of-Abuse-Screening-Technology.html

GLOBENEWSWIRE
04 Oct 2022

https://www.globenewswire.com/news-release/2022/07/13/2479082/0/en/GBS-Inc-Announces-Key-Milestone-in-Prospective-Study-Comparing-Glucose-in-Oral-Fluids-and-Blood.html

GLOBENEWSWIRE
13 Jul 2022

https://www.globenewswire.com/news-release/2022/06/16/2464364/0/en/GBS-INC-Announces-Adjournment-of-2022-Annual-Meeting-of-Stockholders-to-July-13-2022.html

GLOBENEWSWIRE
16 Jun 2022

https://www.globenewswire.com/news-release/2022/06/16/2463961/0/en/GBS-Inc-Enters-into-Exclusivity-Agreement-for-an-Acquisition-of-Unique-Point-of-Care-Diagnostic-Screening-Technology-Focused-on-Opioids-and-Drugs-of-Abuse.html

GLOBENEWSWIRE
16 Jun 2022

https://www.globenewswire.com/news-release/2022/05/16/2444306/0/en/GBS-Inc-to-Present-at-the-H-C-Wainwright-Global-Investment-Conference.html

GLOBENEWSWIRE
16 May 2022

https://www.globenewswire.com/news-release/2022/05/13/2443082/0/en/GBS-Inc-to-Hold-Virtual-2022-Annual-Shareholder-Meeting-on-Thursday-June-16-2022-at-4-00pm-ET.html

GLOBENEWSWIRE
13 May 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty